导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | 0.59% | 2061/4773 |
| 近一周 | -2.56% | 2547/5462 |
| 近一月 | -6.16% | 3465/5421 |
| 近一季 | -10.49% | 3505/5209 |
| 近半年 | -4.56% | 2549/4920 |
| 近一年 | 5.04% | 1641/4366 |
| 近两年 | 61.46% | 1175/2954 |
| 近三年 | 33.64% | 910/2253 |
| 成立以来 | 103.60% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
-0.41% 1790/4961 |
17.41% 1469/5312 |
- - |
- - |
| 2025 | 30.54% 1307/4813 |
3.02% 1216/3635 |
0.30% 2710/4076 |
27.59% 1301/4524 |
-0.98% 2762/4813 |
| 2024 | 8.17% 1582/3463 |
-3.47% 1504/2808 |
-0.87% 855/3014 |
14.26% 2019/3129 |
-1.08% 1579/3463 |
| 2023 | -15.62% 1654/2656 |
5.36% 792/2280 |
-6.26% 1610/2385 |
-9.40% 1813/2515 |
-5.70% 1466/2655 |
| 2022 | -24.44% 1216/2207 |
-17.74% 1252/1919 |
9.11% 299/2016 |
-15.64% 1331/2113 |
-0.20% 1575/2208 |
| 2021 | 7.66% 492/1822 |
-5.94% 965/1255 |
11.90% 358/1330 |
-3.70% 656/1466 |
6.21% 225/1822 |
| 2020 | 45.37% 218/1250 |
-1.85% 244/1028 |
22.34% 210/1067 |
9.79% 622/1164 |
10.27% 602/1184 |
| 2019 | 37.39% 335/1092 |
32.36% 176/754 |
-9.95% 705/804 |
5.38% 152/850 |
9.38% 228/918 |
| 2018 | -35.18% 574/834 |
- - |
- - |
- - |
-15.63% 610/691 |
| 2017 | 17.61% 222/714 |
- - |
- - |
- - |
- - |
| 2016 | -21.19% 454/605 |
- - |
- - |
- - |
- - |
| 2015 | 32.59% 69/575 |
- - |
- - |
- - |
- - |
| 2014 | 8.03% 215/237 |
- - |
- - |
- - |
- - |
| 2013 | 14.86% 27/186 |
- - |
- - |
- - |
- - |
| 2012 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 万家中证港股通创新药ETF | 1.5896 | 28.31% |
| 景顺长城中证港股通创新药ETF | 1.6507 | 28.23% |
| 港股医疗 | 0.9366 | 28.18% |
| 港股医疗ETF | 1.4282 | 28.15% |
| 港股通医疗ETF工银 | 0.9464 | 28.06% |
| 港股通医疗ETF华宝 | 0.9577 | 27.97% |
| 天弘恒生沪深港创新药精选50ETF发起联接C | 1.2844 | 27.92% |
| 天弘恒生沪深港创新药精选50ETF | 0.8437 | 27.35% |
| 万家中证港股通创新药ETF发起式联接A | 1.3863 | 27.32% |
| 万家中证港股通创新药ETF发起式联接C | 1.3856 | 27.27% |
| 易方达中小企业100(LOF)A VS. 长安沪深300非周期A(740101) |